Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals Inc.

www.regeneron.com

Latest From Regeneron Pharmaceuticals Inc.

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago. 

Biosimilars Generic Drugs

AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition

Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
Liver & Hepatic Deals

New EMA Filings: Speedy Review For Lanadelumab But Cemiplimab Gets Standard Treatment

Shire and Regeneron/Sanofi are among the companies that have recently submitted investigational new treatments for approval across the EU. 
Europe Review Pathway

Dupixent Stopped at UK Gate For AD As EMA Agrees To Review It In Asthma

Dupixent has been initially rejected by NICE to treat eczema on cost grounds, but Sanofi remains hopeful of UK entry - and the biologic's overall promise.

Reimbursement Cost Effectiveness
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regeneron Pharmaceuticals Inc.
  • Senior Management
  • Leonard S Schleifer, MD, PhD, Pres. & CEO
    Robert E Landry, SVP, Fin. & CFO
    George D Yancopoulos, MD, PhD, Pres. & CSO
  • Contact Info
  • Regeneron Pharmaceuticals Inc.
    Phone: (914) 847-7000
    777 Old Saw Mill River Rd.
    Tarrytown, NY 10591
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register